42207 Evaluating disparities in the current landscape of clinical trials for vitiligo

Background: Vitiligo is a progressive autoimmune skin condition that can be visually disfiguring, but historically there have been few treatments that are universally effective or widely available. New therapies are continually being evaluated through clinical trials. We sought to describe this current state of ongoing research. We searched for studies indexed on PubMed using clinical trial filter and ClinicalTrials.gov for phase II and III trials with search term “vitiligo.” Data collected included timeframe, sponsorship, funding, blinding, intervention type, and patient demographics including age, sex, race, ethnicity, and type of vitiligo. 285/472 articles were included. 13,568 total patients were enrolled in the clinical trials (mean age 30.95). Of studies reporting gender breakdown, 55.49% of patients were women and 44.51% were men. 110 studies considered Fitzpatrick skin type of participants, and 92 provided breakdowns (I – 1.3%; II – 8.9%; III – 45.2%; IV – 33.9%; V – 9.4%; VI – 1.2%). The majority of blinded studies were single blinded (69), and 28 studies included a quality-of-life (QoL) metric as an outcome.